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Summary
Stop mutations are known to disrupt gene function in
different ways. They both give rise to truncated poly-
peptides because of the premature-termination codons
(PTCs) and frequently affect the metabolism of the cor-
responding mRNAs. The analysis of neurofibromin tran-
scripts from different neurofibromatosis type 1 (NF1)
patients revealed the skipping of exons containing PTCs.
The phenomenon of exon skipping induced by nonsense
mutations has been described for other disease genes,
including the CFTR (cystic fibrosis transmembrance
conductance regulator) gene and the fibrillin gene. We
characterized several stop mutations localized within a
few base pairs in exons 7 and 37 and noticed complete
skipping of either exon in some cases. Because skipping
of exon 7 and of exon 37 does not lead to a frameshift,
PTCs are avoided in that way. Nuclear-scanning mech-
anisms for PTCs have been postulated to trigger the
removal of the affected exons from the transcript. How-
ever, other stop mutations that we found in either NF1
exon did not lead to a skip, although they were localized
within the same region. Calculations of minimum-free-
energy structures of the respective regions suggest that
both changes in the secondary structure of the mRNA
and creation or disruption of exonic sequences relevant
for the splicing process might in fact cause these different
splice phenomena observed in the NF1 gene.
Introduction
The effects of stop mutations have been studied in dif-
ferent genes, and three possible outcomes have been
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demonstrated. In genes such as the b-globin gene, the
triosephosphate-isomerase gene, the methylmalonyl-
CoA mutase gene, and the T-cell receptor-b gene, it has
been shown that stop mutations are able to affect mRNA
metabolism and to reduce the amount of detectable
mRNA (Daar and Maquat 1988; Baserga and Benz
1992; Ogasawara et al. 1994; Maquat 1995; Carter et
al. 1996). Also, in the neurofibromatosis type 1 (NF1)
gene, a correlation between a high proportion of stop
mutations and unequal expression of the two alleles
could be found (Hoffmeyer et al. 1994, 1995). Less com-
monly, mRNA containing a nonsense mutation is trans-
lated and results in a truncated protein (Lehrman et al.
1987; Fojo et al. 1989). The third possible outcome is
an abnormally spliced mRNA induced by a premature-
termination codon (PTC) in the skipped exon. This has
been demonstrated previously in several human genetic
diseases, such as Fanconi anemia, cystic fibrosis, Marfan
syndrome, gyrate atrophy, and Hurler syndrome (Bach
et al. 1993; Dietz et al. 1993; Gibson et al. 1993; Hull
et al. 1994). Very recently, PTC-induced skipping of
exon 37 of the NF1 gene has been reported by Messiaen
et al. (1997).
NF1, or von Recklinghausen neurofibromatosis (MIM
162200 [http://www3.ncbi.nlm.nih.gov:80/htbin-post/
Omim/dispmim?162200), is one of the most common
autosomal dominant disorders, affecting ∼1/3,000 in-
dividuals. The disease is characterized by cafe´-au-lait
spots, multiple neurofibromas and Lisch nodules of the
iris, and an increased predisposition to certain malig-
nancies (Huson and Hughes 1994). The NF1 gene (GDB
120231 [http://www.gdb.org]) was identified on human
chromosome 17 by positional cloning in 1990 (Cawthon
et al. 1990; Viskochil et al. 1990; Wallace et al. 1990).
It spans ∼350 kb of genomic DNA and contains 60
exons (Danglot et al. 1995; Li et al. 1995). Numerous
screening methods have found different types of muta-
tions in the NF1 gene. The great majority (60%–70%)
of the NF1 gene mutations reported to the NNFF In-
ternational NF1 Genetic Analysis Consortium (Korf
1997) and to the Human Gene Mutation Database (Car-
diff) (1997) are truncating mutations. The consequence
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of all these nonsense mutations should be a shortened
neurofibromin, which, however, has not been detected
by western blotting thus far.
The large number of stop mutations found in the NF1
gene prompted us to look specifically for this type of
mutation, by applying the protein-truncation test (PTT)
(Roest et al. 1993). We detected nearby stop mutations
in exon 7 of the NF1 gene, one of which leads to the
skip of the exon in which the mutation is located. Like-
wise, reanalysis of different stop mutations in exon 37
of the NF1 gene previously found by temperature gra-
dient–gel electrophoresis (TGGE) revealed PTC-induced
exon skipping in some cases. In all cases the known
splice-relevant genomic DNA sequences flanking the ex-
ons were unaltered. In addition, the PTCs leading to
exon skipping did not seem to be located in sequence
motifs that are known to function as splicing enhancers.
In the present article, examples of exon skipping as a
consequence of stop mutations in the respective exons
of the NF1 gene are reported. Special emphasis is laid
on the differing effects that various PTCs that are short
distance from each other exert on the splicing of the
affected exon. Our data suggest that both changes in the
secondary structure of the mRNA and creation or dis-
ruption of exonic sequences relevant for the splicing pro-
cess might cause these different splice phenomena.
Material and Methods
RNA Preparations and Reverse Transcription (RT)
Material.—Fresh blood or cell cultures (fibroblast-like
cells from neurofibromas or melanocytes from normally
pigmented skin and from cafe´-au-lait macules) from NF1
patients were used.
RNA isolation.—RNA isolation was performed with
the RNeasy total RNA purification kit (Qiagen). A so-
lution of 600 ml RLT-lysis buffer and 1.5 ml fresh blood
(∼107 cells) was microspun to produce 1.5–7.5 mg total
RNA.
cDNA synthesis.—cDNA synthesis was performed by
the SuperScript preamplification system (BRL Gibco).
The cDNA reaction was performed in a 20-ml reaction
volume containing 2–3 mg total RNA, 1.5 mg random
hexamers (BRL Gibco), 0.5 mg single-stranded binding
protein (Promega), 20 units RNAsin (Promega), 4 mM
each dNTP, and 300 units Superscript II RT (BRL
Gibco). cDNA was stored at 20C.
PTT
RT-PCR.—Hot-start PCR reactions to amplify each
of the five overlapping segments required that 2.5–3 ml
cDNA be added to a lower-phase PCR mixture con-
taining 1 # PCR buffer (50 mM KCl, 10 mM Tris ph
8.3, and 2 mM MgCl2), 0.8 mM each dNTP, and 10
pmol each primer (primer sequences were as described
elsewhere [Heim et al. 1995]), in a total volume of 40
ml. A wax gem (Perkin-Elmer) was added to each tube.
Reaction mixtures were heated to 80C for 5 min, fol-
lowed by cooling to room temperature. A 10-ml upper-
phase mixture containing 1 # PCR buffer, 0.25 mg sin-
gle-stranded binding protein, and 2.5 units Taq poly-
merase (Pharmacia) was layered onto the solidified wax.
Reactions were performed in a Perkin Elmer Cetus ther-
mal cycler (model 9600), under the following conditions:
95C for 1 min; 40 cycles of 95C for 30 s, 61.5C for
30 s, and 72C for 90 s; and 10 min at 72C. The PCR
products were analyzed by agarose gel electrophoresis.
In vitro transcription/translation and analysis of pep-
tides.—For each in vitro transcription/translation reac-
tion, 4–9.5 ml PCR product (volume was dependent on
the quality of the PCR product) and 0.5 ml 35S-methi-
onine (specific activity 11,000 Ci/mmol; Amersham)
were added to the commercially available TNT Cou-
pled Reticulocyte Lysate System (Promega). Reactions
were performed under conditions recommended by the
manufacturer, with one exception: for all components,
only a one-half volume was added to the PTT reaction
(e.g., 12.5 ml TNT Rabbit Reticulocyte Lysate). After
incubation of the complete reaction for 1.5 h at 30C,
5 ml of the reaction was added to 5 ml loading buffer
(10% glycerol, 5% 2-mercaptoethanol, 2% SDS, and
0.1% bromphenol blue), was heated for 5 min, and then
was placed on ice. Samples were subjected to electro-
phoresis in a 14% SDS-polyacrylamide gel for 1.5–2 h
at 40 mA (Rainbow 14C methylated protein [Amersham]
was used as a protein-weight marker). The gel was fixed
in a solution of 40% methanol and 10% acetic acid and
dried for 1.5 h at 80C in a gel dryer. The synthesized
polypeptides were visualized by means of a Phospho-
Imager (Molecular Dynamics) after the gel had been ex-
posed overnight to a special film slide (Molecular
Dynamics).
Sequence Analysis
Single-stranded DNA was obtained by alkali dena-
turation of biotinylated PCR products and separation
with streptavidin-coated magnetic beads (Dynal). Solid-
phase sequencing was performed with a Sequenase V.
2.0 kit from United States Biochemicals.
RFLP Analysis and AccI Restriction
RT-PCR fragments were produced by means of primer
sequences that have been described elsewhere (Hoff-
meyer et al. 1995). The PCR products were digested with
AccI in a reaction volume of 15 ml containing 10 U
restriction enzyme and 1 # restriction buffer (50 mM
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Figure 1 Exon 7 skipping: RT-PCR analysis. The agarose gel
was stained by ethidium bromide. PCR products were derived from
cDNA of NF1 patients U-NF259 and U-NF262 (lanes 2 and 3). Lane
1, 100-bp ladder.
Table 1
Stop Mutations and Their Effect on RNA Splicing
Patient Exon Mutation mRNA Level
Expression
of Two
NF1
Alleles
U-NF259 7 C910T
(R304X)
Exon 7 skipping Unequal
expression
U-NF262 7 918delT; stop
codon 947–949
Normal splicing Not
determined
B-NF2/3 37 C6792A
(Y2264X)
Exon 37 skipping Equal
expression
B-NF4/5 37 C6792A
(Y2264X)
Exon 37 skipping Equal
expression
B-NF6/7/8 37 6790insTT;
stop codon
6806–6808
Normal splicing Equal
expression
B-NF9 37 6789delTTAC;
stop codon
6806–6808
Normal splicing Equal
expression
U-NF33 37 6789delTTAC;
stop codon
6806–6808
Normal splicing Not
determined
Tris-HCl pH 8.0 and 10 mM MgCl2) for 1 h at 37C.
The restriction fragments were analyzed by means of
agarose gel electrophoresis.
Minimum-Free-Energy Structures
The calculation of minimum-free-energy structures is
based on a dynamic programming algorithm originally
developed by Zucker and Stiegler (1981). The partition-
function algorithm is based on the work of McCaskill
(1990). The energy parameters are taken from Turner
et al. (1988). The version of the program used was RNA-
fold 1.00.42
Results
PTT Analysis
In the PTT, which is based on mRNA analysis, not
only nonsense mutations but also aberrant splice prod-
ucts are detected as additional RT-PCR fragments prior
to the actual check of the reading frame. After RT-PCR,
which is the first step of the PTT analysis, NF1 patient
U-NF259 showed a shortened PCR fragment in addition
to the expected one (fig. 1). Further analyses of the re-
spective cDNA region revealed that the size differences
of the PCR fragments were based on deletion of exon
7. The common causes of splicing defects are mutations
either (a) in the consensus sequences of the donor or
acceptor splice sites or (b) around the branch point. In
the case of this NF1 patient, however, a stop mutation
was identified in exon 7 when the genomic DNA was
sequenced. This finding prompted us to reanalyze, at the
mRNA level, NF1 patients in whom TGGE had iden-
tified stop mutations in exon 37 (Robinson et al. 1995;
Bo¨ddrich et al. 1997). Among the nine patients from five
families, all patients with the Y2264X mutation showed
skipping of exon 37, whereas the others did not (see
table 1 and fig. 2). Likewise, PTT identified, in exon 7
in patient U-NF262, a further stop mutation that did
not cause exon skipping (table 1 and fig. 1). Both the
removal of exon 7 and the removal of exon 37 result in
an in-frame coupling of the flanking exons, as has been
described for other genes (Dietz et al. 1993; Gibson et
al. 1993).
Analysis of Splicing-Relevant Sequence Motifs
Although all of the nonsense mutations found in exon
37 are located within only a few base pairs (fig. 3), they
exert quite different effects on splicing. In the case of
the direct stop mutation (C6792A) in exon 37, as well
as in the case of the small deletion (6789delTTAC) and
the small insertion (6790insTT), sequence analyses at
the DNA level showed that all sequence motifs (e.g.,
splice sites or branch points), which are normally in-
volved in the splicing process, are unaltered (data not
shown). This applies also to the mutations found in exon
7. In addition, we also quantified the splice-site scores
for exon 7, as well as those for exon 37, using a scoring
system described by Shapiro and Senapathy (1987); but
all scores are within a normal range (exon 7 had a 3′
splice-site score of 79.5 and a 5′ splice-site score of 79.9;
and exon 37 had a 3′ splice-site score of 87.7 and a 5′
splice-site score of 86.6).
These results indicated that exon skipping apparently
has to be attributed to the mutations themselves. As
shown in figure 3, the mutations 6790insTT and
6789delTTAC cause a frameshift that, in both cases,
results in a stop codon at position 6806–6808 (UGA).
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RT-PCR of the affected area revealed, exclusively, tran-
scripts of normal size (except for the few inserted/deleted
base pairs; fig. 2), indicating that the stop codon at this
position does not interfere with the subsequent splicing
process. In contrast, the recurrently found direct stop
mutation C6792A (UAA) in exon 37 leads to a skipping
of this exon.
Analysis of Expression of the Two NF1 Alleles
As in our previous studies (Hoffmeyer et al. 1994,
1995), we looked also for the expression of the two NF1
alleles in these cases. The expression studies for the mu-
tations in exon 37, which did not cause exon skipping
(table 1), were performed by means of an expressed poly-
morphic RsaI restriction site in exon 5 of the NF1 gene
(Hoffmeyer and Assum 1994). In the case of exon skip-
ping, we measured the band intensities of the two types
of transcripts after RT-PCR (wild-type and mutant al-
leles). Interestingly, in the case of the C6792A mutation
in exon 37, the level of the shortened transcript was not
reduced (fig. 2).
In contrast, in the case of the stop mutation (C910T)
detected in exon 7, a diminished level of the shortened
transcript was found (fig. 1). However, the longer of the
two RT-PCR products could be a homogeneous wild-
type product, or, alternatively, it could contain unknown
portions of an amplification product from the cDNA of
the mutant message that was not abnormally spliced. To
clarify this possibility, we utilized, in exon 7, an AccI
restriction site that was affected by the stop mutation
(C910T; see table 1). This enabled us to distinguish the
two types of amplification products of equal size. After
RT-PCR and a subsequent AccI restriction, the larger
PCR product was totally digested, indicating that it rep-
resents only the wild-type allele of this NF1 patient.
Calculations of Minimum-Free-Energy Structures
Calculations of minimum-free-energy structures, by
application of the computer program RNAfold (Zucker
and Stiegler 1981; Turner et al. 1988; McCaskill 1990)
have revealed the following remarkable results with re-
gard to exons 7 and 37. In the case of exon 7 both the
wild-type sequence and the sequence including the mu-
tation that did not lead to exon skipping (i.e., 918delT)
showed comparable secondary structures (fig. 4a and b).
In contrast, the direct stop mutation (C910T) causes a
secondary structure that is completely different from the
other two structures calculated for exon 7 (fig. 4c).
Hence, a dramatic change of the secondary structure
might in fact cause the skipping of exon 7. The calcu-
lations for all three mutations in exon 37, including the
wild-type sequence, showed no differences between the
secondary structures, apparently because the bases in-
volved form an impaired loop (data not shown). How-
ever, as shown in figure 5, because of the CrA substi-
tution in exon 37 (i.e., C6792A), a new branch-point
sequence apparently emerges.
Discussion
There have been a considerable number of reports of
PTC-induced exon skipping (e.g., see Bach et al. 1993;
Dietz et al. 1993; Gibson et al. 1993; Hull et al. 1994).
Different hypotheses about the mechanism of this phe-
nomenon have been proposed (Dietz and Kendzior
1994; Carter et al. 1996; Maquat 1996), but at present
a unifying model that reconciles all observations does
not exist.
In the case of the C6792A mutation in exon 37 of the
NF1 gene, expression studies revealed equal expression
of the two alleles. This finding also indicates that the
prevention of normal splicing by this mutation is com-
plete—that is, the mutation C6792A causes a nonleaky
splicing anomaly. The uniformity of the wild-type copy
was also ascertained by sequence analysis (data not
shown). If, as well, the corresponding shortened neu-
rofibromin and the normal neurofibromin are being syn-
thesized in equal amounts, a dominant negative mech-
anism may cause the disease in these particular cases.
The in-frame splicing of exon 37 renders this a real pos-
sibility. Similarly, Dietz et al. (1993) have reported a
relatively high amount of an abnormally spliced tran-
script of the fibrillin gene (FBN1), caused by a stop mu-
tation in exon 51. This gene encodes a structural protein,
the expression of which, in both allelic forms, is in ac-
cordance with the dominant negative mechanism pro-
posed for Marfan syndrome (Dietz et al. 1992). To our
knowledge, there exist no data suggesting that polypep-
tides translated from messages lose individual exons by
abnormal skipping.
These results are in contrast to observations made in
other genes, such as the ornithine aminotransferase gene,
where the amount of cDNA amplified from the abnor-
mally spliced transcript has been seen to be significantly
lower than that amplified from the normal-size tran-
script (Dietz et al. 1993). Likewise, in the case of the
stop mutation (C910T) in exon 7 of the NF1 gene, a
diminished level of the abnormally spliced transcript was
found. This finding does not, however, allow any con-
clusion with respect to the intranuclear events. The di-
minished amount of the shortened mutant transcript,
which lacks exon 7, along with its stop codon, can still
be explained in at least two ways. The alternative, ab-
normal splicing that leads to the skipping of exon 7
could be incomplete, and the mutant variety of RNA
molecules still containing exon 7 could become de-
graded. Alternatively, abnormal splicing of the mutant
RNA precursor could be complete, but part of the ab-
Hoffmeyer et al.: Stop Codons of NF1 as Splice Affectors 273
Figure 2 Exon 37 skipping: RT-PCR analysis. The agarose gel was stained by ethidium bromide. PCR products are derived from cDNA
of NF1 patients B-NF2, B- NF3, B-NF6, B-NF7, B-NF8,B-NF4, B-NF5, and B-NF9 (lanes 2– 9, respectively). Lane 1, Size marker.
Figure 3 Localization of different stop mutations within exon 37 of the NF1 gene.
normally shortened message could be subjected to in-
tranuclear or cytoplasmatic degradation.
The skipping of constitutive exons has, however, been
demonstrated not only for stop mutations but also for
an intraexonic deletion and a missense mutation that
activates a cryptic splice site (Matsuo et al. 1991; Wa-
kamatsu et al. 1992). In the case of the 52-bp intraexonic
deletion found in exon 19 of the dystrophin gene, near
the 5′ splice junction of intron 19, the recognition of this
site could be hampered by the small size of the truncated
exon (Matsuo et al. 1991). The deletion (6789delTTAC)
and the insertion (6790insTT) found in exon 37 of the
NF1 gene do not have an effect on splicing (whereas the
intraexonic deletion in the dystrophin gene does have
this effect), and these mutations are located distant from
each of the splice sites and do not significantly change
the size of the exon. In addition, an intraexonic silent
mutation has recently been shown to cause skipping of
the comparable exon in FBN1 (Liu et al. 1997). That a
PTC can also inhibit the normal splicing of the affected
exon has been demonstrated by Milstein and colleagues,
who analyzed the splicing phenotypes of minigene con-
structs from a k light-chain gene, using nuclear extracts
in a cell-free system (Aoufouchi et al. 1996).
The phenomenon of PTC-induced exon skipping has
given rise to a debate about the underlying mechanism
(Dietz and Kendzior 1994; Carter et al. 1996; Maquat
1996). The discussion is primarily concerned with the
problem of the intranuclear recognition of the PTCs,
which followed by their partial or complete removal via
illegitimate skipping of the exon containing the affected
codon. Urlaub et al. (1989) have suggested such a nu-
clear-scanning model, in which specific intranuclear fac-
tors are able to scan the primary transcript for PTCs. A
274 Am. J. Hum. Genet. 62:269–277, 1998
Figure 4 Minimum-free-energy structures for exon 7. The sequences contain / 50 bases downstream and upstream, respectively, of
the 3′ splice site. a, Wild-type sequence of intron 6 and exon 7. b, Sequence of intron 6 and exon 7, including mutation 918delT. c, Sequence
of intron 6 and exon 7, including mutation C910T.
Figure 5 Minimum-free-energy structure for exon 37, including
mutation C6792A. The sequence contains/ 120 bases downstream
and upstream, respectively, of the 3′ splice site.
similar but more far-reaching concept has been devel-
oped by Dietz and Kendzior (1994), on the basis of their
studies utilizing minigene constructs from exons 50–52
of FBN1, with experimental variation of a naturally oc-
curring nonsense codon. The fact that, with one excep-
tion, normal splicing was completely restored when the
reading frame was shifted, so that the three bases of the
former PTCs came to belong to consecutive sense co-
dons, was considered to be strong evidence in favor of
an intranuclear-scanning mechanism based on the rec-
ognition of the reading frame. Dietz and Kendzior
(1994) assigned to this mechanism the important func-
tion of the maintenance of an open reading frame. A
similar proposal has been made by Carter et al. (1996).
The common denominator of these ideas is the existence
of a scanning mechanism that recognizes PTCs and trig-
gers exon skipping, but a role for alterations of the sec-
ondary structure of the transcript, which result from the
base exchanges, is also being taken into consideration,
either as a contributory factor (Dietz and Kendzior
1994) or as an alternative explanation (Maquat 1996).
If primarily concerned with the maintenance of an
open reading frame, such a scanning mechanism should
be capable of recognizing the PTCs that have arisen
downstream of the three frameshift mutations here de-
scribed (table 1), if not these frameshifts themselves. Our
findings, together with the aforementioned exceptions,
suggest that (a) the scanning mechanism either is leaky
or has a context specificity with yet unknown preferences
or (b) does not exist at all.
Purin-rich sequences that serve as splicing enhancers
by interacting with splicing factors and with cis-acting
intronic elements have been described for exons of sev-
eral genes, such as the adenosine deaminase (ADA) gene
and the fibronectin gene (Lavigueur et al. 1993; Santis-
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teban et al. 1995). Some types of nonsense mutations
localized in such enhancer sequences are able to cause
the skipping of the respective exon, because of a dis-
ruption of the interaction between an exonic splicing
enhancer and serine arginine proteins (Watakabe et al.
1993; Santisteban et al. 1995; Chiara et al. 1996). For
example, a nonsense mutation (R142X; CGArTGA) in
a patient with severe combined immunodeficiency dis-
ease has been found to cause skipping of exon 5 of the
ADA gene. This mutation is located within a purine-rich
segment of exon 5 in the ADA gene, distant from both
splice junctions. There is, however, in the putative en-
hancer sequence, no change of the number of purines
that is due to the mutation in exon 5 (Santisteban et al.
1995). In this regard, a reduction of the splicing-en-
hancer effect could be observed in vitro by introducing
a thymidine (T) into purine-rich sequences (Tanaka et
al. 1994). Furthermore, in the hypoxanthine-guanine
phosphoribosyltransferase (HPRT) gene, five of six ex-
onic point mutations that caused exon skipping were
substitutions by T, two of which also created nonsense
codons (Steingrimsdottir et al. 1992).
In addition to purine-rich enhancers, non–purine-rich
sequences can also function as splicing enhancers (Stak-
nis and Reed 1994; Lynch and Maniatis 1995). Thus,
although all the mutations found in exons 7 and 37 of
the NF1 gene are localized in a heterogeneous sequence
of bases, the possibility that such splicing enhancer se-
quences exist in these regions cannot be excluded.
Besides the known splicing-relevant sequences, such
as splice sites and branch-point motifs, additional in-
tronic sequences have been described as playing a role
in the splicing process. Sirand-Pugnet et al. (1995) re-
ported, in the chicken b-tropomyosin gene, an (A/
U)GGG repeat with a potential role as an enhancer of
the splicing reaction at the level of spliceosome assembly.
Recently, Cogan et al. (1997) have published two mu-
tations in intron 3 of the human growth hormone (GH)
gene that lead to exon 3 skipping. Both mutations are
located 28 bp downstream from the 5′ splice site, within
a XGGG repeat similar to the repetitions found in the
chicken b-tropomyosin gene. Cogan et al. (1997) suggest
that the repeats may regulate alternative splicing in the
human GH gene. This sequence motif does not occur in
the known 210 bp of the 5′ end of intron 7, whereas
intron 37 contains a number of scattered single copies
of the motif at greater distances from the 5′ splice site.
With regard to an influence of alterations of the sec-
ondary structure on the splicing process, Steingrimsdot-
tir et al. (1992) have published interesting data. For exon
8 of the HPRT mRNA, a potential stem-loop structure
could be shown. A total of seven mutations have been
identified in this exon, all of which are localized at dif-
ferent positions within this structure. Three of these mu-
tations do affect splicing of exon 8 to varying degrees.
It could be shown that the mutations at paired C residues
lead to much more aberrant splicing than the alteration
of the non–base-paired G residue. Maintenance of this
stem-loop structure may be essential for correct splic-
ing—for example, for exposure of the splice sites. The
disruption of such a structure by specific mutations may
be an explanation of splicing abnormalities (Steingrims-
dottir et al. 1992). We have calculated the minimum-
free-energy structures for the direct and the indirect stop
mutations that we have found in exons 7 and 37 of the
NF1 gene. Such computations demonstrate, at the exon-
intron junctions and the branch-point regions, charac-
teristic secondary structures that were surprisingly in-
variant to the sizes of the flanking sequences taken into
account (W. Leistner, unpublished data). These calcu-
lations have revealed a secondary structure for the mu-
tation (C910T) in exon 7, which is completely different
from the calculated structures of the wild-type sequence
and of the mutant sequence (918delT) (fig. 4) (the latter
two sequences have indistinguishable secondary struc-
tures). We therefore suggest that, in the case of the direct
stop mutation in exon 7, the altered secondary structure
might in fact cause the anomalous splice phenomenon.
We are aware of the hypothetical nature of the calculated
secondary structures, whose relationship to the in vivo
situation remains to be elucidated. These structures do,
however, provide a feasible starting point for the com-
parison of the possible structural consequences of var-
ious sequence alterations.
In conclusion, mutations generating PTCs may result
in exon skipping, by various mechanisms. The NF1 gene
stop mutations C910T and C6792A trigger the skipping
of the affected exon in different ways but apparently
independently of any reading -frame surveillance mech-
anism that might have evolved for either the mainte-
nance of an open reading frame (Dietz and Kendzior
1994) and/or nuclear down-regulation of aberrant tran-
scripts bearing PTCs (Carter et al. 1996). The direct stop
mutation (C910T) in exon 7 possibly interferes with the
normal splicing process, because of the specifically al-
tered secondary structure that was not observed with the
unskipped stop mutation found nearby in exon 7. It is
conceivable that the altered secondary structure in the
respective area of the pre-mRNA leads to a covering of
the respective splice sites, including the upstream branch
point, as has been speculated for some mutations in exon
8 of the HPRT gene (Steingrimsdottir et al. 1992). With
regard to exon 37, the direct stop mutation C6792A
seems to generate a new branch-point sequence in an
inappropriate position that might interfere with the in-
itial splice-site recognition and spliceosomal complex as-
sembly (Reed 1996), whereas the other two stop mu-
tations found in the immediate vicinity do not affect the
splicing process. What the skipping phenomena ob-
served in both exons seem to have in common is an
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impaired exon definition, caused by a particular stop
mutation. In our view, exon definition is the immediate
consequence of the interaction between the spliceosomal
complex (and its auxiliary factors) and the appropriate
sequence signals. This process is dependent on more or
less stringent structural constraints, so that alterations
of the secondary structure of the sequences involved may
or may not perturb the splicing process, depending on
the kind and the extent of the affected sequences. The
generation and the abrogation of splicing-signal se-
quences with their characteristic secondary structures
will be important factors to consider in this process.
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